BRAF Targets in Melanoma: Biological Mechanisms, Resistance, and Drug Discovery
This volume contains a collection of writings from the leaders in the fields of Molecular Biology and Melanoma Research which will begin to tell the ever-expanding story of the most recent findings, discoveries, and potential of BRAF-directed targets in melanoma. Recent research has shown that BRAF...
Gespeichert in:
| Format: | Elektronisch E-Book |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
New York, NY
Springer New York
2015
|
| Ausgabe: | 1st ed. 2015 |
| Schriftenreihe: | Cancer Drug Discovery and Development
|
| Schlagworte: | |
| Online-Zugang: | UBR01 Volltext |
| Zusammenfassung: | This volume contains a collection of writings from the leaders in the fields of Molecular Biology and Melanoma Research which will begin to tell the ever-expanding story of the most recent findings, discoveries, and potential of BRAF-directed targets in melanoma. Recent research has shown that BRAF inhibitors are effective for a short period of time, but there is little hope that these drugs as single agents will lead to durable benefit in a majority of patients. Among scientists and researchers who work in drug discovery, there is a lot of interest in the development of molecularly targeted cancer agents. Namely, the identification of a molecular target, the selection of molecules which effectively inhibit this target. What is starkly different about the development of this class of compounds, however, is that the mechanism of action of these agents are not as straightforward as was once previously assumed and the mechanisms of resistance that tumor cells employ to evade complete destruction are unlike any that have been described before. These discoveries in addition to utilization of modern molecular biology techniques have led to a series of hypotheses regarding which other types of molecules could be used in combination with BRAF-inhibitors in hopes of revolutionizing the potential of therapeutics in melanoma |
| Beschreibung: | Melanoma: Historical Context -- Melanoma Pathogenesis -- Molecular Diagnostics and Tumor Mutational Analysis -- Clinical Utility of BRAF-targeted therapy in Melanoma -- The Ethics of Randomized Trials in Oncology -- Parallel and Serial Blockade Strategies in BRAF-Mutant Melanoma -- Targeting the cell cycle and p53 in combination with BRAF-directed therapy -- Combination BRAF-directed therapy and immunotherapy -- Moving Forward: Making BRAF-Targeted Therapy Better |
| Beschreibung: | 1 Online Ressource (VIII, 204 Seiten, 26 Illustrationen, 21 Illustrationen in Farbe) |
| ISBN: | 9781493921430 |
| DOI: | 10.1007/978-1-4939-2143-0 |
Internformat
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV046815942 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 200721s2015 |||| o||u| ||||||eng d | ||
| 020 | |a 9781493921430 |9 978-1-4939-2143-0 | ||
| 024 | 7 | |a 10.1007/978-1-4939-2143-0 |2 doi | |
| 035 | |a (ZDB-2-SME)978-1-4939-2143-0 | ||
| 035 | |a (OCoLC)1190911924 | ||
| 035 | |a (DE-599)BVBBV046815942 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 | ||
| 082 | 0 | |a 614.5999 | |
| 245 | 1 | 0 | |a BRAF Targets in Melanoma |b Biological Mechanisms, Resistance, and Drug Discovery |c edited by Ryan J. Sullivan |
| 250 | |a 1st ed. 2015 | ||
| 264 | 1 | |a New York, NY |b Springer New York |c 2015 | |
| 300 | |a 1 Online Ressource (VIII, 204 Seiten, 26 Illustrationen, 21 Illustrationen in Farbe) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 490 | 0 | |a Cancer Drug Discovery and Development | |
| 500 | |a Melanoma: Historical Context -- Melanoma Pathogenesis -- Molecular Diagnostics and Tumor Mutational Analysis -- Clinical Utility of BRAF-targeted therapy in Melanoma -- The Ethics of Randomized Trials in Oncology -- Parallel and Serial Blockade Strategies in BRAF-Mutant Melanoma -- Targeting the cell cycle and p53 in combination with BRAF-directed therapy -- Combination BRAF-directed therapy and immunotherapy -- Moving Forward: Making BRAF-Targeted Therapy Better | ||
| 520 | |a This volume contains a collection of writings from the leaders in the fields of Molecular Biology and Melanoma Research which will begin to tell the ever-expanding story of the most recent findings, discoveries, and potential of BRAF-directed targets in melanoma. Recent research has shown that BRAF inhibitors are effective for a short period of time, but there is little hope that these drugs as single agents will lead to durable benefit in a majority of patients. Among scientists and researchers who work in drug discovery, there is a lot of interest in the development of molecularly targeted cancer agents. Namely, the identification of a molecular target, the selection of molecules which effectively inhibit this target. What is starkly different about the development of this class of compounds, however, is that the mechanism of action of these agents are not as straightforward as was once previously assumed and the mechanisms of resistance that tumor cells employ to evade complete destruction are unlike any that have been described before. These discoveries in addition to utilization of modern molecular biology techniques have led to a series of hypotheses regarding which other types of molecules could be used in combination with BRAF-inhibitors in hopes of revolutionizing the potential of therapeutics in melanoma | ||
| 650 | 4 | |a Cancer research | |
| 650 | 4 | |a Molecular biology | |
| 650 | 4 | |a Medical microbiology | |
| 650 | 4 | |a Pharmacology | |
| 700 | 1 | |a Sullivan, Ryan J. |e Sonstige |4 oth | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9781493921447 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9781493921423 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9781493953486 |
| 856 | 4 | 0 | |u https://doi.org/10.1007/978-1-4939-2143-0 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
| 912 | |a ZDB-2-SME | ||
| 940 | 1 | |q ZDB-2-SME_2015 | |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-032224411 | ||
| 966 | e | |u https://doi.org/10.1007/978-1-4939-2143-0 |l UBR01 |p ZDB-2-SME |q ZDB-2-SME_2015 |x Verlag |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804181625272008704 |
|---|---|
| adam_txt | |
| any_adam_object | |
| any_adam_object_boolean | |
| building | Verbundindex |
| bvnumber | BV046815942 |
| collection | ZDB-2-SME |
| ctrlnum | (ZDB-2-SME)978-1-4939-2143-0 (OCoLC)1190911924 (DE-599)BVBBV046815942 |
| dewey-full | 614.5999 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 614 - Forensic medicine; incidence of disease |
| dewey-raw | 614.5999 |
| dewey-search | 614.5999 |
| dewey-sort | 3614.5999 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| discipline_str_mv | Medizin |
| doi_str_mv | 10.1007/978-1-4939-2143-0 |
| edition | 1st ed. 2015 |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03485nmm a2200469zc 4500</leader><controlfield tag="001">BV046815942</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">200721s2015 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781493921430</subfield><subfield code="9">978-1-4939-2143-0</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/978-1-4939-2143-0</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-2-SME)978-1-4939-2143-0</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1190911924</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV046815942</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">614.5999</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">BRAF Targets in Melanoma</subfield><subfield code="b">Biological Mechanisms, Resistance, and Drug Discovery</subfield><subfield code="c">edited by Ryan J. Sullivan</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">1st ed. 2015</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">New York, NY</subfield><subfield code="b">Springer New York</subfield><subfield code="c">2015</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online Ressource (VIII, 204 Seiten, 26 Illustrationen, 21 Illustrationen in Farbe)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Cancer Drug Discovery and Development</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Melanoma: Historical Context -- Melanoma Pathogenesis -- Molecular Diagnostics and Tumor Mutational Analysis -- Clinical Utility of BRAF-targeted therapy in Melanoma -- The Ethics of Randomized Trials in Oncology -- Parallel and Serial Blockade Strategies in BRAF-Mutant Melanoma -- Targeting the cell cycle and p53 in combination with BRAF-directed therapy -- Combination BRAF-directed therapy and immunotherapy -- Moving Forward: Making BRAF-Targeted Therapy Better</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">This volume contains a collection of writings from the leaders in the fields of Molecular Biology and Melanoma Research which will begin to tell the ever-expanding story of the most recent findings, discoveries, and potential of BRAF-directed targets in melanoma. Recent research has shown that BRAF inhibitors are effective for a short period of time, but there is little hope that these drugs as single agents will lead to durable benefit in a majority of patients. Among scientists and researchers who work in drug discovery, there is a lot of interest in the development of molecularly targeted cancer agents. Namely, the identification of a molecular target, the selection of molecules which effectively inhibit this target. What is starkly different about the development of this class of compounds, however, is that the mechanism of action of these agents are not as straightforward as was once previously assumed and the mechanisms of resistance that tumor cells employ to evade complete destruction are unlike any that have been described before. These discoveries in addition to utilization of modern molecular biology techniques have led to a series of hypotheses regarding which other types of molecules could be used in combination with BRAF-inhibitors in hopes of revolutionizing the potential of therapeutics in melanoma</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cancer research</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Molecular biology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Medical microbiology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmacology</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sullivan, Ryan J.</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9781493921447</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9781493921423</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9781493953486</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1007/978-1-4939-2143-0</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-2-SME</subfield></datafield><datafield tag="940" ind1="1" ind2=" "><subfield code="q">ZDB-2-SME_2015</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-032224411</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1007/978-1-4939-2143-0</subfield><subfield code="l">UBR01</subfield><subfield code="p">ZDB-2-SME</subfield><subfield code="q">ZDB-2-SME_2015</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| id | DE-604.BV046815942 |
| illustrated | Not Illustrated |
| index_date | 2024-07-03T15:00:10Z |
| indexdate | 2024-07-10T08:54:38Z |
| institution | BVB |
| isbn | 9781493921430 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-032224411 |
| oclc_num | 1190911924 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR |
| owner_facet | DE-355 DE-BY-UBR |
| physical | 1 Online Ressource (VIII, 204 Seiten, 26 Illustrationen, 21 Illustrationen in Farbe) |
| psigel | ZDB-2-SME ZDB-2-SME_2015 ZDB-2-SME ZDB-2-SME_2015 |
| publishDate | 2015 |
| publishDateSearch | 2015 |
| publishDateSort | 2015 |
| publisher | Springer New York |
| record_format | marc |
| series2 | Cancer Drug Discovery and Development |
| spelling | BRAF Targets in Melanoma Biological Mechanisms, Resistance, and Drug Discovery edited by Ryan J. Sullivan 1st ed. 2015 New York, NY Springer New York 2015 1 Online Ressource (VIII, 204 Seiten, 26 Illustrationen, 21 Illustrationen in Farbe) txt rdacontent c rdamedia cr rdacarrier Cancer Drug Discovery and Development Melanoma: Historical Context -- Melanoma Pathogenesis -- Molecular Diagnostics and Tumor Mutational Analysis -- Clinical Utility of BRAF-targeted therapy in Melanoma -- The Ethics of Randomized Trials in Oncology -- Parallel and Serial Blockade Strategies in BRAF-Mutant Melanoma -- Targeting the cell cycle and p53 in combination with BRAF-directed therapy -- Combination BRAF-directed therapy and immunotherapy -- Moving Forward: Making BRAF-Targeted Therapy Better This volume contains a collection of writings from the leaders in the fields of Molecular Biology and Melanoma Research which will begin to tell the ever-expanding story of the most recent findings, discoveries, and potential of BRAF-directed targets in melanoma. Recent research has shown that BRAF inhibitors are effective for a short period of time, but there is little hope that these drugs as single agents will lead to durable benefit in a majority of patients. Among scientists and researchers who work in drug discovery, there is a lot of interest in the development of molecularly targeted cancer agents. Namely, the identification of a molecular target, the selection of molecules which effectively inhibit this target. What is starkly different about the development of this class of compounds, however, is that the mechanism of action of these agents are not as straightforward as was once previously assumed and the mechanisms of resistance that tumor cells employ to evade complete destruction are unlike any that have been described before. These discoveries in addition to utilization of modern molecular biology techniques have led to a series of hypotheses regarding which other types of molecules could be used in combination with BRAF-inhibitors in hopes of revolutionizing the potential of therapeutics in melanoma Cancer research Molecular biology Medical microbiology Pharmacology Sullivan, Ryan J. Sonstige oth Erscheint auch als Druck-Ausgabe 9781493921447 Erscheint auch als Druck-Ausgabe 9781493921423 Erscheint auch als Druck-Ausgabe 9781493953486 https://doi.org/10.1007/978-1-4939-2143-0 Verlag URL des Erstveröffentlichers Volltext |
| spellingShingle | BRAF Targets in Melanoma Biological Mechanisms, Resistance, and Drug Discovery Cancer research Molecular biology Medical microbiology Pharmacology |
| title | BRAF Targets in Melanoma Biological Mechanisms, Resistance, and Drug Discovery |
| title_auth | BRAF Targets in Melanoma Biological Mechanisms, Resistance, and Drug Discovery |
| title_exact_search | BRAF Targets in Melanoma Biological Mechanisms, Resistance, and Drug Discovery |
| title_exact_search_txtP | BRAF Targets in Melanoma Biological Mechanisms, Resistance, and Drug Discovery |
| title_full | BRAF Targets in Melanoma Biological Mechanisms, Resistance, and Drug Discovery edited by Ryan J. Sullivan |
| title_fullStr | BRAF Targets in Melanoma Biological Mechanisms, Resistance, and Drug Discovery edited by Ryan J. Sullivan |
| title_full_unstemmed | BRAF Targets in Melanoma Biological Mechanisms, Resistance, and Drug Discovery edited by Ryan J. Sullivan |
| title_short | BRAF Targets in Melanoma |
| title_sort | braf targets in melanoma biological mechanisms resistance and drug discovery |
| title_sub | Biological Mechanisms, Resistance, and Drug Discovery |
| topic | Cancer research Molecular biology Medical microbiology Pharmacology |
| topic_facet | Cancer research Molecular biology Medical microbiology Pharmacology |
| url | https://doi.org/10.1007/978-1-4939-2143-0 |
| work_keys_str_mv | AT sullivanryanj braftargetsinmelanomabiologicalmechanismsresistanceanddrugdiscovery |